In plain words

In one 12-week trial, people taking NMN rated their sleep better than people on a dummy pill. In a second 12-week trial at the same daily amount, sleep changed about equally in the NMN and comparison groups. A small study of single doses found no change in sleep scores.

The short answer

The two randomized trials split. Morifuji and colleagues (2024) compared 250 mg a day with placebo for 12 weeks in 60 people and found lower daytime dysfunction and total sleep index scores, a sign of better sleep. Kim and colleagues (2022) tested 250 mg a day for 12 weeks in 108 people and found no significant difference between groups over time. A before-after study of single 100, 250 and 500 mg doses in 10 healthy men (Irie and colleagues, 2019) found no change in sleep scores. Certainty is low, because the two trials are small and disagree, and the third study had no control group.

The 60-second version

Every study in the video is listed below, with its quote.

Watch on YouTube

Where the evidence sits

Sleep scores improved

■ Randomized trial, Morifuji et al., 2024 · 60 people · 12 weeks

No difference found

■ Randomized trial, Kim et al., 2022 · 108 people · 12 weeks
■ Before-after study, Irie et al., 2019 · 10 people

■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data

Evidence weight4343 / 100?

Who says what

SourceFindingDesignPeopleDose and lengthFunding and independence
Morifuji et al., 2024Better sleep scores than placeboRandomized, placebo-controlled trial60250 mg a day for 12 weeksNot in ledger
Kim et al., 2022No significant difference over timeRandomized trial, four groups108250 mg a day for 12 weeksNot in ledger
Irie et al., 2019No change in sleep scoreBefore-after study, no control group10 healthy menSingle doses of 100, 250 and 500 mgNot in ledger
Morifuji et al., 2024

Better sleep scores than placebo

Design
Randomized, placebo-controlled trial
People
60
Dose and length
250 mg a day for 12 weeks
Funding
Not in ledger
Kim et al., 2022

No significant difference over time

Design
Randomized trial, four groups
People
108
Dose and length
250 mg a day for 12 weeks
Funding
Not in ledger
Irie et al., 2019

No change in sleep score

Design
Before-after study, no control group
People
10 healthy men
Dose and length
Single doses of 100, 250 and 500 mg
Funding
Not in ledger

Did people on NMN sleep better than people on placebo?

Morifuji and colleagues (2024) compared 250 mg of NMN a day with placebo for 12 weeks in 60 people. They scored sleep with the Pittsburgh questionnaire, where lower scores mean better sleep:

The NMN group had improved sleep quality at 12 weeks relative to the placebo group as evidenced by lower scores for "Daytime dysfunction" and "Global PSQI" on the Pittsburgh Sleep Questionnaire.

Kim and colleagues (2022) tested the same 250 mg a day for 12 weeks in 108 people, on the same questionnaire, and asked whether scores changed differently between groups over time:

There was no statistically significant interaction in sleep quality as assessed by the PSQI.

Terms: PSQI is the Pittsburgh Sleep Quality Index.

Did the time of day matter?

Kim's 108 people were split into four groups, one of which took NMN in the afternoon. At 250 mg a day for 12 weeks, the authors report that this afternoon group had the largest effect sizes, while the group differences over time were not statistically significant:

the effect sizes of sleep latency (d = 0.56), daytime dysfunction score (d = 0.72), sleep quality score (d = 0.80), and total PSQI global score (d = 0.68) in the NMN_PM group were the largest among the four groups

Terms: NMN_PM is the afternoon NMN group; d is a standard measure of effect size. The ledger has no breakdown for the other three groups.

What happened after a single dose?

Irie and colleagues (2019) gave 10 healthy men single oral doses of 100, 250 and 500 mg and compared measurements before and after, with no placebo group. The ledger has no follow-up duration for it. They report:

Results of ophthalmic examination and sleep quality score showed no differences before and after the intervention.

Why the sources disagree

Both trials gave 250 mg a day for 12 weeks and used the same questionnaire, in 60 and 108 people, so dose and length do not separate them. The comparisons differ. Morifuji reports two scores against placebo, while Kim tested whether four groups, including an afternoon NMN group, changed differently over time. The ledger has no funding details and no description of the participants for either trial. Irie's study is a different kind of measurement: single doses of 100 to 500 mg in 10 men, with no control group.

What would settle it

A preregistered placebo-controlled trial of 250 mg of NMN a day for 12 weeks, sized to detect a change in the total Pittsburgh Sleep Quality Index score as its main outcome, with separate morning and afternoon NMN arms and a sleep measure beyond the questionnaire, such as wrist actigraphy. A matching result from a second research group would raise the certainty from low to moderate.

How this page was made

The 3 sources are the studies in the Longevity Circle NMN ledger that measured sleep quality in people, found through a literature search for human NMN studies. A published trial protocol on chronic insomnia was left out because it is limited to patients with insomnia and has no results. Adverse event claims were left out because none bears directly on sleep. Every claim was copied word for word from its source into the ledger and checked against the original text, and a person approved each one. "Contested" means independent studies point in both directions; certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.

The ledger holds only 3 studies on this question.

Changelog: 23 Sep 2026, first version, 3 sources.